Brief: NeuroStar Advanced Therapy Receives FDA Clearance As First-Line Add-On Treatment For Adolescents With Depression
25/03/2024 14:27
March 25 (Reuters) - Neuronetics Inc STIM.O :
* NEUROSTAR® ADVANCED THERAPY RECEIVES FDA CLEARANCE AS A
FIRST-LINE ADD-ON TREATMENT FOR ADOLESCENTS WITH DEPRESSION
Source text for Eikon: ID:nGNX10mrXF
Further company coverage: STIM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Neuronetics
See all newsNeuronetics Inc reports results for the quarter ended June 30 - Earnings Summary
Neuronetics Q2 revenue beats estimates on Greenbrook clinic strength
Neuronetics Inc expected to post a loss of 12 cents a share - Earnings Preview
Brief: Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Neuronetics Appoints Nir Naor Chief Financial Officer Announces Additional Management Changes